A HEPATOTOXICITY STUDY REGARDING BONE METASTASATED PROSTATE ADENOCARCINOMA HORMONOTHERAPY.
ROXANA LUCACIU^1*, LUCIA DICAN², CORINA IONESCU¹,
MARIUS BOJIŢĂ³, ANDREEA L. ARSENE⁴
1,2,3University of Medicine and Pharmacy “Iuliu Haţieganu” Cluj-
Napoca, Pasteur 4/6
1Department of Pharmaceutical Biochemistry and Clinical laboratory
2Department of Medical Biochemistry
3Department of Drug Analysis
4University of Medicine and Pharmacy „Carol Davila” Bucharest,
Faculty of Pharmacy, Department of Biochemistry
*corresponding author: roxanaluc@yahoo.com


Download Full Article

Abstract:

The aim of the present study was to establish which therapeutical scheme used in the hormonotherapy (HT) of metastasated prostate adenocarcinoma at bone level was less hepatotoxic, on long-term therapy (period of 4 years). For this purpose, the levels of serical transaminases activity at well established time intervals have been determined, throughout the hormonotherapy period and after the hormonotherapy was stopped due to hepatotoxicity. Usually, for treating metastasated prostate adenocarcinoma, a combined hormonotherapy is necessary. Flutamide and cyproterone are synthetic substances for the treatment of metastasated prostate adenocarcinoma that bind to androgen receptors and block the cellular effects of circulating testosterone and dihydrotestosterone (androgen receptor antagonists). The most incriminated in generating hepatotoxicity is the combined therapy with Flutamide, the incidence being more elevated than in Flutamide monotherapy. Cyproterone is also incriminated in unleashing hepatotoxicity. In the case of Cyproterone the incidence of generated hepatotoxicity was the same for combined and mono-hormonotherapy..

Top